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Management and prevention of
thrombotic stent occlusion
We read with a great interest, the paper by
Wenaweser et al.1 who report the efﬁcacy
and outcome of emergency percutaneous
coronary interventions in patients with
stent thrombosis.
Recently, we published our data on 1519
consecutive patients who underwent 2020
stent implantations and were discharged on
dual anti-platelet therapy. We compared
the short- and long-term risks of thrombotic
stent occlusion (TSO) and mortality in
patients given clopidogrel or ticlopidine.2,3
The rates of TSO during the ﬁrst year of
follow-up, in our study, were 1.8, 0.7, and
2.8% in the whole group, the ticlopidine
group and the clopidogrel group (P, 0.01).
A multivariate model showed that clopido-
grel (vs. ticlopidine) treatment was the
sole predictor of TSO (OR ¼ 5.4, 95%
CI ¼ 1.2–24.1, P ¼ 0.028). Of even greater
concern, clopidogrel treatment was
associated with an increased risk of 1-year
mortality (OR ¼ 1.8, 95% CI ¼ 1.2–2.8). Our
data are in agreement with those published
by Mueller et al.4 who reported that
the extended follow-up data of their
initial randomized trial which compared
clopidogrel with ticlopidine after stenting.
Similar to our ﬁndings, these investigators
reported a signiﬁcantly higher rate of
mortality, both overall and cardiovascular,
in the clopidogrel arm.
Wenaweser et al.1 report a prevalence
of 1.6% of stent thrombosis, a rate that
is similar to ours. Clopidogrel was used in
many more of their TSO patients than
ticlopidine (86 and 14%, respectively).
While the focus of the study of Wenaweser
et al.1 was on the treatment of TSO,
we believe that in light of the previous
ﬁndings, it would be of great interest
to know whether Wenaweser et al.1
could report the rates of TSO in their
clopidogrel- and ticlopidine-treated patients,
respectively. Such information from
another well-studied cohort may shed
further light on the potential role of
ticlopidine vs. clopidogrel in the long-term
prevention of TSO.
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The management and prevention
of thrombotic stent occlusion: reply
Dual antiplatelet therapy with aspirin and
thienopyridines has been shown superior to
treatment with oral anticoagulation and
aspirin alone in the prevention of major
adverse cardiac events following coronary
stent implantation.1 The therapeutic
beneﬁt of ticlopidine was somewhat limited
by rare but potentially serious adverse
effects such as neutropenia and thrombo-
cytopenia. The advent of clopidogrel was
associated with a superior haematological
safety proﬁle but comparable efﬁcacy in
three randomized trials and has largely
replaced the use of ticlopidine.2–4
Notwithstanding, the comparative studies
had some limitations: (1) the trials were
underpowered to detect small but poten-
tially important differences in the incidence
of stent thrombosis; (2) the studies differed
with respect to the loading dose regimen;
and (3) the follow-up period was limited
to 30 days. In light of these limitations,
the report of Dr Wolak and colleagues of a
higher incidence of stent thrombosis with
clopidogrel (2.8%) than ticlopidine (0.7%)
in an all-comer population of 1519 con-
secutive patients undergoing bare metal
stent implantation is of interest. Their
observation is echoed by the extended
follow-up data of the randomized trial
reported by Mueller et al.5 and our own
experience. Thus, we have previously inves-
tigated the incidence of stent thrombosis
following bare metal stent implantation in
4500 consecutive patients.6 While the
overall rate of stent thrombosis was 0.8%,
thrombotic stent occlusion occurred in
1.9% of patients with clopidogrel and in
0.6% of patients with ticlopidine treatment
(P, 0.05). The mechanism for the observed
difference in efﬁcacy between ticlopidine
and clopidogrel remains unclear but has
been related to differences in drug–drug
interaction as well as dose and length of
treatment with the respective thienopyri-
dine. Stent thrombosis has gained even
more importance in the era of drug
eluting stents and future studies with
long-term follow-up will have to determine
the optimal antiplatelet therapy.
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Comment on pregnancy and aortic
root growth in the Marfan syndrome
Meijboom and coworkers1 reported on the
aortic root growth rate of women with
Marfan syndrome during pregnancy. They
could not ﬁnd a signiﬁcant increase in the
aortic root diameter in 31 pregnancies of
23 patients and concluded that ‘Pregnancy
in women with Marfan syndrome seems to
be relatively safe up to an aortic root
diameter of 45 mm’.
We believe that it is too early to draw such
a conclusion. All statistical tests performed
in this study were aimed to ﬁnd any
growth. These tests failed, but a power
analysis to determine the case number
necessary to ﬁnd any differences was not
performed. The authors even reported on
one woman with an aortic dissection during
pregnancy and on an increased growth of
the aortic root during long-term follow-up
in those patients with an aortic root
diameter .40 mm at baseline in a subgroup
analysis.
We recently lost one of our patients, a
36-year-old woman with aortic coarctation
and bicuspid aortic valve. These patients
usually have structural abnormalities in
the aortic medial wall predisposing to
dilatation, aneurysm, and rupture, which
are similar but less pronounced than
those described in Marfan syndrome.2,3
This woman died from aortic rupture at
the 36th week of her second pregnancy.
Her ascending aorta measured 40–41 mm
and did not show any progression of
diameter assessed several times by echo-
cardiography as well as by helical CT prior
to her second pregnancy. Unfortunately,
the patient was not seen in our centre
during pregnancy, and no consecutive
imaging was performed.
Summarizing, this study did not provide
real evidence for the conclusion that
‘Pregnancy in women with Marfan syndrome
seems to be relatively safe up to an
aortic root diameter of 45 mm’. We should
recommend to monitor all pregnant women
with Marfan syndrome very carefully and
closely, as suggested in many previous
studies,4,5 because aortic dissection does
not only depend on aortic diameter pro-
gression and may also occur in Marfan
patients with a normal aortic diameter.5
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Comment on pregnancy and aortic
root growth in the Marfan syndrome:
reply
Thank you for the opportunity to respond to
the comment from Hager and co-workers. It
is an immense tragedy when a young woman
dies during pregnancy. We agree with Hager
and co-workers that there is no deﬁnite
safe aortic root diameter for women
with Marfan syndrome to get pregnant.
Dissections may occur at normal aortic
diameters in patients with Marfan syndrome.
Should we therefore advise all women
with Marfan syndrome against pregnancy?
During recent years, a panel of inter-
national experts has reached consensus
that pregnancy can be tolerated in women
with Marfan syndrome with a slightly
dilated aortic root.1 This expert consensus
is being validated by our ﬁndings, which
indicate that pregnancy is relatively safe in
women with Marfan syndrome and an aortic
root diameter up to 45 mm.2 However,
women with a previous dissection should
not get pregnant. We agree with Hager
et al. that all patients with Marfan syndrome
deserve close and careful monitoring before,
during, and after pregnancy. Before preg-
nancy, all women should undergo a magnetic
resonance angiogram to investigate if there
is dilatation in other parts of the aorta.
Also, frequent echocardiographic imaging
should be performed throughout pregnancy
and the postpartum period to check for pro-
gressive aortic dilatation. In the future other
risk factors for aortic dissection, such as
aortic elasticity, might become available to
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